CBD Calmed Inflamed Intestines in Mice Without Affecting Normal Gut Movement
CBD selectively reduced gut hypermotility caused by inflammation without slowing normal intestinal movement, working through CB1 receptors and the FAAH enzyme pathway.
Quick Facts
What This Study Found
Researchers tested CBD's effects on both normal and inflamed mouse intestines. In healthy mice, CBD had no effect on gut motility, meaning normal digestive movement was unaffected.
However, in mice with croton oil-induced intestinal inflammation, CBD normalized the excessive gut motility (hypermotility) that accompanies inflammation. This selectivity, affecting only abnormal movement while leaving normal function intact, is a desirable property for any potential medication.
The anti-hypermotility effect was blocked by the CB1 receptor antagonist rimonabant but not by the CB2 antagonist, opioid antagonist, or alpha2-adrenergic antagonist, indicating a CB1-mediated mechanism. CBD's effect was also abolished when FAAH (the enzyme that breaks down anandamide) was inhibited, suggesting CBD works by enhancing anandamide levels through FAAH.
In isolated intestinal tissue, CBD inhibited acetylcholine-induced contractions from both normal and inflamed intestines, showing it has direct smooth muscle effects as well.
Key Numbers
CBD normalized croton oil-induced hypermotility. Effect blocked by rimonabant (CB1 antagonist). Effect NOT blocked by CB2 antagonist, naloxone (opioid), or yohimbine (alpha2-adrenergic). Effect abolished by FAAH inhibition.
How They Did This
In vivo gut motility was measured by tracking an orally administered fluorescent marker through the small intestine. Inflammation was induced with croton oil. Various receptor antagonists and enzyme inhibitors were used to identify the mechanism. In vitro contractility was measured in isolated ileum.
Why This Research Matters
Inflammatory bowel diseases cause painful gut hypermotility. Most anti-motility drugs (like loperamide) reduce all gut movement, including normal digestion. CBD's selective action on only inflamed, hyperactive intestines suggests it could relieve symptoms without causing constipation.
The Bigger Picture
This study provided preclinical support for CBD in inflammatory bowel disease, a condition where patients frequently report using cannabis for symptom relief. The selective mechanism, affecting only inflamed tissue, is particularly relevant for drug development.
What This Study Doesn't Tell Us
Mouse intestinal inflammation models don't fully replicate human IBD. The doses used may not correspond to achievable human doses. Only acute effects were examined. The croton oil model is a chemical irritant, not an immune-mediated model like Crohn's disease.
Questions This Raises
- ?Does CBD show the same selective anti-motility effect in human IBD?
- ?Would oral CBD at standard doses achieve sufficient intestinal concentrations?
- ?Could CBD complement existing IBD medications?
Trust & Context
- Key Stat:
- CBD reduced inflamed gut hypermotility but did not affect normal intestinal movement
- Evidence Grade:
- This is a well-designed animal study with thorough mechanistic investigation, providing moderate preclinical evidence that requires human validation.
- Study Age:
- Published in 2008. Clinical trials of CBD for IBD have since been initiated, with some showing promising results for symptom management.
- Original Title:
- Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.
- Published In:
- British journal of pharmacology, 154(5), 1001-8 (2008)
- Authors:
- Capasso, R, Borrelli, F, Aviello, G, Romano, B, Scalisi, C, Capasso, F, Izzo, A A
- Database ID:
- RTHC-00304
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could CBD help with IBS or Crohn's disease?
This mouse study showed CBD selectively reduced inflammation-driven gut overactivity, which is promising for conditions like IBD. However, mouse models don't fully represent human disease, and clinical trial evidence for CBD in IBD is still developing.
Why is it significant that CBD didn't affect normal gut movement?
Most anti-diarrheal drugs (like Imodium) slow all gut movement, causing constipation. CBD's selective action on only inflamed, overactive intestines means it could potentially relieve symptoms without disrupting normal digestion.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00304APA
Capasso, R; Borrelli, F; Aviello, G; Romano, B; Scalisi, C; Capasso, F; Izzo, A A. (2008). Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.. British journal of pharmacology, 154(5), 1001-8. https://doi.org/10.1038/bjp.2008.177
MLA
Capasso, R, et al. "Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.." British journal of pharmacology, 2008. https://doi.org/10.1038/bjp.2008.177
RethinkTHC
RethinkTHC Research Database. "Cannabidiol, extracted from Cannabis sativa, selectively inh..." RTHC-00304. Retrieved from https://rethinkthc.com/research/capasso-2008-cannabidiol-extracted-from-cannabis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.